Hexima Limited (ASX:HXL)
Biotechnology ResearchView the employees at
Hexima Limited (ASX:HXL)-
Shaily Vasa Research Officer at Hexima Limited
-
Greater Melbourne Area
-
Rising Star
Om Srivastava Vice President of Technical Operations at Hexima-
San Diego, California, United States
-
Top 1%
Geoffrey Kempler Board Director-
Rising Star
Marilyn Anderson Professor of Biochemistry | Company Director | Biotechnology | Strategy-
Top 1%
Overview
Hexima is a clinical stage, anti-infectives focused biotechnology company engaged in the research and development of plant defensin peptides for applications as human therapeutics. Our lead product candidate, pezadeftide (formally HXP124) applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting an Australian phase IIb clinical trial testing pezadeftide for the treatment of onychomycosis. Hexima holds granted, long-life patents protecting pezadeftide in major markets globally.
-